Fumihiro Hirayama Selected Research

Y754

4/2004

Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Helicobacter pylori.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fumihiro Hirayama Research Topics

Disease

3	Infections 05/2018 - 03/2002
1	Disseminated Intravascular Coagulation 01/2007
1	Inflammation (Inflammations) 01/2007
1	Leukemia 09/2004
1	Neoplasms (Cancer) 09/2004
1	Fever (Fevers) 09/2004
1	Peptic Ulcer (Peptic Ulcers) 04/2004
1	Abscess 03/2002
1	Communicable Diseases (Infectious Diseases) 03/2002
1	Septic Shock (Toxic Shock Syndrome) 03/2002
1	Staphylococcal Infections 03/2002
1	Metaplasia 01/2002
1	Gastritis 01/2002
1	Atrophy 01/2002
1	Carcinoid Tumor (Carcinoid) 01/2002
1	Stomach Ulcer (Gastric Ulcer) 01/2002

Drug/Important Bio-Agent (IBA)

1	Panton-Valentine leukocidinIBA 05/2018
1	AntitoxinsIBA 05/2018
1	Neutralizing AntibodiesIBA 05/2018
1	AntithrombinsIBA 01/2007
1	Peptide Hydrolases (Proteases)FDA Link 01/2007
1	Dacarbazine (DIC)FDA LinkGeneric 01/2007
1	CytokinesIBA 01/2007
1	Interferon Type IIBA 09/2004
1	Antiviral Agents (Antivirals)IBA 09/2004
1	Pharmaceutical PreparationsIBA 09/2004
1	limitinIBA 09/2004
1	Clarithromycin (Biaxin)FDA LinkGeneric 04/2004
1	Y754IBA 04/2004
1	Immunoglobulins (Immunoglobulin)IBA 03/2002
1	AntibodiesIBA 03/2002
1	Dextrans (Dextran)FDA Link 03/2002
1	Staphylococcal enterotoxin FIBA 03/2002
1	Intravenous Immunoglobulins (IVIG)FDA Link 03/2002
1	Therapeutic UsesIBA 01/2002

Therapy/Procedure

3	Therapeutics 04/2004 - 01/2002